دورية أكاديمية
أعرض في EDS

The Expression of Serglycin Is Required for Active Transforming Growth Factor β Receptor I Tumorigenic Signaling in Glioblastoma Cells and Paracrine Activation of Stromal Fibroblasts via CXCR-2.

التفاصيل البيبلوغرافية
العنوان: The Expression of Serglycin Is Required for Active Transforming Growth Factor β Receptor I Tumorigenic Signaling in Glioblastoma Cells and Paracrine Activation of Stromal Fibroblasts via CXCR-2.
المؤلفون: Manou D; Biochemistry, Biochemical Analysis and Matrix Pathobiology Research Group, Laboratory of Biochemistry, Department of Chemistry, University of Patras, 26504 Patras, Greece., Golfinopoulou MA; Biochemistry, Biochemical Analysis and Matrix Pathobiology Research Group, Laboratory of Biochemistry, Department of Chemistry, University of Patras, 26504 Patras, Greece., Alharbi SND; Department of Chemistry, College of Science, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia., Alghamdi HA; Department of Chemistry, College of Science, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia., Alzahrani FM; Department of Chemistry, College of Science, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia., Theocharis AD; Biochemistry, Biochemical Analysis and Matrix Pathobiology Research Group, Laboratory of Biochemistry, Department of Chemistry, University of Patras, 26504 Patras, Greece.
المصدر: Biomolecules [Biomolecules] 2024 Apr 10; Vol. 14 (4). Date of Electronic Publication: 2024 Apr 10.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101596414 Publication Model: Electronic Cited Medium: Internet ISSN: 2218-273X (Electronic) Linking ISSN: 2218273X NLM ISO Abbreviation: Biomolecules Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, 2011-
مواضيع طبية MeSH: Glioblastoma*/metabolism , Glioblastoma*/pathology , Glioblastoma*/genetics , Receptors, Interleukin-8B*/metabolism , Receptors, Interleukin-8B*/genetics , Signal Transduction* , Proteoglycans*/metabolism , Proteoglycans*/genetics , Fibroblasts*/metabolism , Fibroblasts*/pathology , Vesicular Transport Proteins*/metabolism , Vesicular Transport Proteins*/genetics, Humans ; Cell Line, Tumor ; Cell Proliferation/genetics ; Paracrine Communication ; Receptor, Transforming Growth Factor-beta Type I/metabolism ; Receptor, Transforming Growth Factor-beta Type I/genetics ; Brain Neoplasms/metabolism ; Brain Neoplasms/pathology ; Brain Neoplasms/genetics ; Gene Expression Regulation, Neoplastic ; Stromal Cells/metabolism ; Stromal Cells/pathology ; Carcinogenesis/genetics ; Carcinogenesis/metabolism ; Carcinogenesis/pathology
مستخلص: Serglycin (SRGN) is a pro-tumorigenic proteoglycan expressed and secreted by various aggressive tumors including glioblastoma (GBM). In our study, we investigated the interplay and biological outcomes of SRGN with TGFβRI, CXCR-2 and inflammatory mediators in GBM cells and fibroblasts. SRGN overexpression is associated with poor survival in GBM patients. High SRGN levels also exhibit a positive correlation with increased levels of various inflammatory mediators including members of TGFβ signaling pathway, cytokines and receptors including CXCR-2 and proteolytic enzymes in GBM patients. SRGN-suppressed GBM cells show decreased expressions of TGFβRI associated with lower responsiveness to the manipulation of TGFβ/TGFβRI pathway and the regulation of pro-tumorigenic properties. Active TGFβRI signaling in control GBM cells promotes their proliferation, invasion, proteolytic and inflammatory potential. Fibroblasts cultured with culture media derived by control SRGN-expressing GBM cells exhibit increased proliferation, migration and overexpression of cytokines and proteolytic enzymes including CXCL-1, IL-8, IL-6, IL-1β, CCL-20, CCL-2, and MMP-9. Culture media derived by SRGN-suppressed GBM cells fail to induce the above properties to fibroblasts. Importantly, the activation of fibroblasts by GBM cells not only relies on the expression of SRGN in GBM cells but also on active CXCR-2 signaling both in GBM cells and fibroblasts.
References: Pharmacol Ther. 2006 Oct;112(1):139-49. (PMID: 16720046)
Biochim Biophys Acta Rev Cancer. 2019 Apr;1871(2):289-312. (PMID: 30703432)
Semin Cancer Biol. 2020 May;62:108-115. (PMID: 31279836)
Front Cell Dev Biol. 2021 Oct 29;9:721897. (PMID: 34778248)
Oncogene. 2008 Feb 21;27(9):1198-207. (PMID: 17828308)
J Biol Chem. 2014 Feb 28;289(9):5499-509. (PMID: 24403068)
Cancers (Basel). 2019 Apr 03;11(4):. (PMID: 30987226)
Thromb Haemost. 2005 Apr;93(4):661-75. (PMID: 15841310)
J Cell Sci. 2003 Jan 15;116(Pt 2):217-24. (PMID: 12482908)
Mol Cell Biochem. 2010 Jul;340(1-2):195-202. (PMID: 20204677)
Matrix Biol. 2019 Jan;75-76:1-11. (PMID: 30130584)
J Neurosci. 2010 Apr 28;30(17):5843-54. (PMID: 20427645)
Arch Biochem Biophys. 2019 Jul 15;669:80-86. (PMID: 31145901)
Exp Cell Res. 2008 Aug 1;314(13):2501-14. (PMID: 18602101)
Oncogene. 2007 Apr 12;26(17):2407-22. (PMID: 17072348)
Matrix Biol. 2019 Jan;75-76:220-259. (PMID: 29128506)
Cancer Cell. 2009 Apr 7;15(4):315-27. (PMID: 19345330)
FEBS J. 2019 Aug;286(15):2830-2869. (PMID: 30908868)
Am J Cancer Res. 2015 Feb 15;5(3):945-55. (PMID: 26045979)
Biochem Biophys Res Commun. 2018 May 15;499(3):506-512. (PMID: 29588174)
Eur J Cancer. 2013 May;49(7):1725-40. (PMID: 23298711)
J Neuroimmunol. 2012 May 15;246(1-2):1-9. (PMID: 22445294)
Front Oncol. 2020 Aug 05;10:1358. (PMID: 32850434)
Dev Dyn. 2018 Mar;247(3):382-395. (PMID: 28722327)
ISRN Dermatol. 2013 Jul 18;2013:597927. (PMID: 23984088)
Oncogenesis. 2017 Jul 10;6(7):e360. (PMID: 28692037)
Int J Mol Sci. 2021 Mar 05;22(5):. (PMID: 33807899)
Clin Transl Med. 2022 Aug;12(8):e1031. (PMID: 35994394)
Oncotarget. 2017 Apr 11;8(15):24815-24827. (PMID: 28445977)
FEBS J. 2013 May;280(10):2342-52. (PMID: 23387827)
J Biochem. 2011 Apr;149(4):405-14. (PMID: 21288887)
FEBS J. 2021 Dec;288(24):6850-6912. (PMID: 33605520)
J Neuroinflammation. 2010 Oct 11;7:62. (PMID: 20937129)
Oncogene. 2018 May;37(19):2515-2531. (PMID: 29449696)
Front Oncol. 2014 Jan 13;3:327. (PMID: 24455486)
Matrix Biol Plus. 2020 Mar 11;6-7:100033. (PMID: 33543029)
Front Surg. 2016 Mar 02;3:11. (PMID: 26973839)
Science. 2014 Jun 20;344(6190):1396-401. (PMID: 24925914)
J Immunol. 2011 Nov 15;187(10):4927-33. (PMID: 22049227)
PLoS One. 2013 Oct 31;8(10):e78157. (PMID: 24205138)
Trends Mol Med. 2021 Oct;27(10):1000-1013. (PMID: 34389240)
Cancer Res. 2011 Apr 15;71(8):3162-72. (PMID: 21289131)
PLoS One. 2012;7(4):e35128. (PMID: 22514714)
Cancer Cell. 2007 Feb;11(2):147-60. (PMID: 17292826)
Am J Pathol. 2014 Dec;184(12):3384-93. (PMID: 25310970)
Cytokine Growth Factor Rev. 2016 Oct;31:61-71. (PMID: 27578214)
Biomed Res Int. 2015;2015:690721. (PMID: 26581653)
Matrix Biol. 2018 Dec;74:35-51. (PMID: 29842969)
J Clin Invest. 2013 Mar;123(3):1348-58. (PMID: 23391723)
FEBS J. 2013 Jun;280(12):2870-87. (PMID: 23601700)
Lab Invest. 2017 May;97(5):498-518. (PMID: 28287634)
J Cell Biochem. 2008 Jun 1;104(3):934-41. (PMID: 18307173)
FEBS Lett. 2015 Jun 22;589(14):1588-97. (PMID: 25957771)
J Biol Chem. 2002 Jun 14;277(24):21352-60. (PMID: 11929865)
J Biol Chem. 2006 Nov 17;281(46):35116-28. (PMID: 16870619)
Biochem Biophys Res Commun. 2000 Jul 5;273(2):521-7. (PMID: 10873638)
J Clin Invest. 2023 Mar 1;133(5):. (PMID: 36856115)
Int J Biochem Cell Biol. 2008;40(6-7):1068-78. (PMID: 18243766)
Front Oncol. 2022 Apr 14;12:868868. (PMID: 35494005)
Onco Targets Ther. 2015 Nov 02;8:3203-9. (PMID: 26586954)
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. (PMID: 34185076)
Acta Neuropathol. 2016 Mar;131(3):365-78. (PMID: 26718201)
Chem Rev. 2018 Sep 26;118(18):9152-9232. (PMID: 30204432)
Eur J Cancer. 2012 Jul;48(10):1550-7. (PMID: 21798735)
Prostate. 2006 Jun 15;66(9):996-1004. (PMID: 16541418)
Eur J Immunol. 2011 Feb;41(2):437-49. (PMID: 21268013)
Oncogene. 2003 Jan 23;22(3):412-25. (PMID: 12545162)
Oncogene. 2013 Nov 21;32(47):5409-20. (PMID: 23524585)
World Neurosurg. 2021 May;149:e758-e765. (PMID: 33540096)
N Engl J Med. 2005 Mar 10;352(10):987-96. (PMID: 15758009)
Cell Stem Cell. 2009 Nov 6;5(5):504-14. (PMID: 19896441)
Eur J Cancer. 2006 Apr;42(6):768-78. (PMID: 16510280)
Methods Mol Biol. 2019;1952:1-20. (PMID: 30825161)
معلومات مُعتمدة: PNURSP-HC2022/6 Princess Nourah bint Abdulrahman University
فهرسة مساهمة: Keywords: extracellular matrix; glioblastoma; proteoglycans; serglycin; tumor microenvironment
المشرفين على المادة: 0 (Receptors, Interleukin-8B)
0 (serglycin)
0 (Proteoglycans)
0 (CXCR2 protein, human)
0 (Vesicular Transport Proteins)
EC 2.7.11.30 (Receptor, Transforming Growth Factor-beta Type I)
تواريخ الأحداث: Date Created: 20240427 Date Completed: 20240427 Latest Revision: 20240520
رمز التحديث: 20240520
مُعرف محوري في PubMed: PMC11048235
DOI: 10.3390/biom14040461
PMID: 38672477
قاعدة البيانات: MEDLINE
الوصف
تدمد:2218-273X
DOI:10.3390/biom14040461